The European Medicines Agency (EMA) has recently updated its webpage on antimicrobial resistance.

The emerging and steady increase of microbes that are resistant to antimicrobial treatments has become a global public health concern that threatens the effective treatment of infectious diseases. Combatting this threat, particularly resistance to antibiotics, is a high priority for EMA and the European medicines regulatory network.

Antimicrobial resistance is when a microbe evolves to become more or fully resistant to antimicrobials which previously could treat it. Antimcirobials include antibiotics, which kill or inhibit the growth of bacteria.

AMR is particularly important for cancer patients as their immune system is very weak from cancer treatments.

Please find the updated webpage with more details here.